---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054486"
form_type: "8-K"
ticker: null
cik: "0001808158"
company_name: "Repare Therapeutics Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:40:24.461472+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Repare Therapeutics reports Q1 net income $13.2M; FDA agrees on RP2D for lunresertib+camonsertib combination

## Summary
- Net income of $13.2M ($0.30 diluted) vs loss of $34.9M a year ago; revenue $52.4M primarily from $40M Roche milestone.
- Cash, equivalents and marketables $237M, sufficient to fund operations at least into mid-2026.
- FDA agreed to RP2D for lunresertib 80mg BID + camonsertib 80mg QD; Grade 3 anemia reduced to 25% from 45%.
- Regained global rights to camonsertib from Roche; cumulative $182.6M received from Roche under collaboration.
- First patient dosed in Phase 1 LIONS trial of PLK4 inhibitor RP-1664; expecting pivotal trial start for lunresertib combo in 2025.

## SEC filing metadata
- accession: 0000950170-24-054486
- form_type: 8-K
- cik: 0001808158
- company_name: Repare Therapeutics Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/0000950170-24-054486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/rptx-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054486
- JSON: https://secwatch.observer/filing/0000950170-24-054486.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054486.txt

## Key facts
- Earnings Releases
  Repare Therapeutics Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024, Repare Therapeutics Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/0000950170-24-054486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.